H&M Molecular Diagnostics, LLC
H&M Molecular Diagnostics, LLC was paid $11.23M by Medicaid between Feb 2020 and Aug 2024, across 27 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 73% of everything it billed.
SAN DIEGO, CA 92121
Next to other Clinical Medical Laboratory providers in California
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,998 | $118K | |
| 2021 | 4,655 | $148K | |
| 2022 | 48,552 | $2.10M | |
| 2023 | 183,935 | $8.85M | |
| 2024incomplete | 503 | $25K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 73% | 113,251 | 93,680 | $8.24M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 23% | 111,975 | 92,997 | $2.55M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.4% | 5,307 | 4,587 | $270K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,274 | 2,471 | $54K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 294 | 284 | $39K |
| 87150 | <1% | 146 | 144 | $22K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 146 | 146 | $21K |
| 87481 | <1% | 293 | 283 | $8K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 394 | 236 | $7K |
| 87640 | <1% | 295 | 285 | $4K | |
| 87500 | <1% | 290 | 281 | $4K | |
| 87653 | <1% | 276 | 269 | $4K |
15 more codes
| 87641 | <1% | 297 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 99 | $3K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | <1% | 1,718 | $2K |
| 87486 | 0% | 77 | $0.00 | |
| 81240 | 0% | 46 | $0.00 | |
| 87581 | 0% | 77 | $0.00 | |
| 0029U | 0% | 44 | $0.00 | |
| 81335 | 0% | 46 | $0.00 | |
| 87652 | 0% | 14 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 54 | $0.00 |
| 87265 | 0% | 77 | $0.00 | |
| 81241 | 0% | 46 | $0.00 | |
| 81291 | 0% | 46 | $0.00 | |
| 87631 | 0% | 17 | $0.00 | |
| 0032U | 0% | 44 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.